ADAR RNA editing in human disease; more to it than meets the I

. 2017 Sep ; 136 (9) : 1265-1278. [epub] 20170914

Jazyk angličtina Země Německo Médium print-electronic

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/pmid28913566

Grantová podpora
621368 EU - International
17615 AIRC IG - International

Odkazy

PubMed 28913566
DOI 10.1007/s00439-017-1837-0
PII: 10.1007/s00439-017-1837-0
Knihovny.cz E-zdroje

We review the structures and functions of ADARs and their involvements in human diseases. ADAR1 is widely expressed, particularly in the myeloid component of the blood system, and plays a prominent role in promiscuous editing of long dsRNA. Missense mutations that change ADAR1 residues and reduce RNA editing activity cause Aicardi-Goutières Syndrome, a childhood encephalitis and interferonopathy that mimics viral infection and resembles an extreme form of Systemic Lupus Erythmatosus (SLE). In Adar1 mouse mutant models aberrant interferon expression is prevented by eliminating interferon activation signaling from cytoplasmic dsRNA sensors, indicating that unedited cytoplasmic dsRNA drives the immune induction. On the other hand, upregulation of ADAR1 with widespread promiscuous RNA editing is a prominent feature of many cancers and particular site-specific RNA editing events are also affected. ADAR2 is most highly expressed in brain and is primarily required for site-specific editing of CNS transcripts; recent findings indicate that ADAR2 editing is regulated by neuronal excitation for synaptic scaling of glutamate receptors. ADAR2 is also linked to the circadian clock and to sleep. Mutations in ADAR2 could contribute to excitability syndromes such as epilepsy, to seizures, to diseases involving neuronal plasticity defects, such as autism and Fragile-X Syndrome, to neurodegenerations such as ALS, or to astrocytomas or glioblastomas in which reduced ADAR2 activity is required for oncogenic cell behavior. The range of human disease associated with ADAR1 mutations may extend further to include other inflammatory conditions while ADAR2 mutations may affect psychiatric conditions.

Zobrazit více v PubMed

EMBO J. 1995 Jul 17;14(14):3563-71 PubMed

Neuroscience. 2000;95(3):869-79 PubMed

Nat Cell Biol. 2015 Mar;17(3):311-21 PubMed

J Biol Chem. 2008 Mar 14;283(11):7251-60 PubMed

Nat Commun. 2016 Jan 27;7:10512 PubMed

Cell Rep. 2014 Nov 20;9(4):1482-94 PubMed

J Biol Chem. 2006 Nov 3;281(44):33386-94 PubMed

Nature. 2000 Jul 6;406(6791):78-81 PubMed

Science. 1999 Jun 11;284(5421):1841-5 PubMed

Nat Commun. 2011;2:319 PubMed

Nature. 2011 Mar 24;471(7339):473-9 PubMed

Nucleic Acids Res. 2017 Apr 7;45(6):3369-3377 PubMed

Cell. 1988 Dec 23;55(6):1089-98 PubMed

Biochemistry. 2000 Oct 24;39(42):12875-84 PubMed

Front Neurosci. 2013 Apr 18;7:61 PubMed

Nat Med. 2013 Feb;19(2):209-16 PubMed

Genome Res. 2011 Sep;21(9):1506-11 PubMed

J Med Genet. 2014 Feb;51(2):76-82 PubMed

Curr Opin Neurobiol. 2007 Jun;17(3):289-97 PubMed

Bioinformatics. 2016 Jul 15;32(14 ):2213-5 PubMed

Neuron. 2013 Oct 16;80(2):415-28 PubMed

Genome Res. 2012 Jul;22(7):1266-81 PubMed

RNA. 2000 May;6(5):755-67 PubMed

EMBO J. 1998 Dec 15;17(24):7505-13 PubMed

Nucleic Acids Res. 2007;35(11):3723-32 PubMed

Science. 1994 Dec 9;266(5191):1709-13 PubMed

Neurobiol Dis. 2012 Mar;45(3):1121-8 PubMed

Immunity. 2011 Jun 24;34(6):866-78 PubMed

Neuroscience. 2011 Aug 25;189:305-15 PubMed

Mol Biol Cell. 2002 Nov;13(11):3822-35 PubMed

Genome Biol. 2015 Jan 13;16:5 PubMed

PLoS One. 2012;7(3):e33720 PubMed

J Cell Sci. 2017 Feb 15;130(4):745-753 PubMed

Neuropharmacology. 2009 Jan;56(1):2-5 PubMed

Int J Cancer. 2013 Apr 15;132(8):1741-50 PubMed

J Biol Chem. 2017 Mar 10;292(10 ):4326-4335 PubMed

Genome Res. 2014 Mar;24(3):365-76 PubMed

RNA Biol. 2017 Feb;14 (2):164-170 PubMed

Hum Genet. 1997 Sep;100(3-4):398-400 PubMed

J Biol Chem. 2007 Aug 3;282(31):22448-59 PubMed

Cell Rep. 2015 Oct 13;13(2):277-89 PubMed

Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12465-70 PubMed

J Biol Chem. 2004 Feb 6;279(6):4952-61 PubMed

Nucleic Acids Res. 2013 Nov;41(21):9786-99 PubMed

Curr Top Microbiol Immunol. 2012;353:197-220 PubMed

Cancer Cell. 2015 Oct 12;28(4):515-528 PubMed

Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10979-83 PubMed

PLoS One. 2011;6(9):e25350 PubMed

Mol Psychiatry. 2008 Nov;13(11):1001-10 PubMed

Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14687-92 PubMed

Exp Neurol. 2016 Jan;275 Pt 1:162-71 PubMed

J Hum Genet. 2015 Nov;60(11):657-64 PubMed

J Biol Chem. 1999 Apr 2;274(14):9472-8 PubMed

Nat Genet. 2012 Nov;44(11):1243-8 PubMed

J Clin Invest. 2013 Jun;123(6):2703-18 PubMed

Genome Biol. 2017 Jul 28;18(1):143 PubMed

Cell. 2010 Mar 19;140(6):771-6 PubMed

Immunology. 2003 May;109(1):15-23 PubMed

Science. 2015 Sep 4;349(6252):1115-20 PubMed

Nat Biotechnol. 2012 Feb 12;30(3):253-60 PubMed

Nat Immunol. 2009 Jan;10(1):109-15 PubMed

Cell. 1987 Feb 27;48(4):599-605 PubMed

PLoS Biol. 2004 Dec;2(12):e391 PubMed

Nat Commun. 2015 Mar 09;6:6355 PubMed

Oncogene. 2013 Feb 21;32(8):998-1009 PubMed

Cell Rep. 2013 Nov 14;5(3):849-60 PubMed

Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14018-23 PubMed

Gene. 2000 May 30;250(1-2):53-60 PubMed

EMBO J. 2009 Oct 21;28(20):3145-56 PubMed

Nature. 1997 May 15;387(6630):303-8 PubMed

Nature. 2009 Oct 8;461(7265):809-13 PubMed

Mol Brain. 2014 Jan 21;7:5 PubMed

RNA Biol. 2017 Jun 22;:1-12 PubMed

Cell. 1987 Feb 27;48(4):607-13 PubMed

J Biol Chem. 2004 Feb 6;279(6):4894-902 PubMed

Bioessays. 2008 Nov;30(11-12):1185-92 PubMed

Nat Genet. 2017 Jan;49(1):146-151 PubMed

EMBO J. 2000 Mar 1;19(5):997-1009 PubMed

J Exp Med. 2014 Apr 7;211(4):613-21 PubMed

Mol Cell Biol. 2001 Nov;21(22):7862-71 PubMed

Cell Rep. 2015 Oct 13;13(2):267-76 PubMed

Cancer Res. 2014 Feb 1;74(3):840-51 PubMed

Cell. 2010 Oct 15;143(2):225-37 PubMed

BMC Genomics. 2016 Sep 29;17(1):766 PubMed

EMBO J. 1994 Dec 1;13(23):5701-11 PubMed

Immunity. 2015 Nov 17;43(5):933-44 PubMed

EMBO J. 2011 Aug 16;30(20):4211-22 PubMed

Cell. 1991 Oct 4;67(1):11-9 PubMed

Neuropsychopharmacology. 2001 May;24(5):478-91 PubMed

Science. 2005 Sep 2;309(5740):1534-9 PubMed

Neuropsychopharmacology. 1999 Aug;21(2 Suppl):82S-90S PubMed

Neurosci Lett. 2003 Aug 7;346(3):169-72 PubMed

Leukemia. 2017 May 09;:null PubMed

Mol Cell Biol. 1995 Oct;15(10):5376-88 PubMed

Int J Oncol. 2017 Feb;50(2):622-630 PubMed

Nature. 2011 Apr 28;472(7344):481-5 PubMed

Hum Mol Genet. 2000 Sep 22;9(15):2297-304 PubMed

Mol Cell Biol. 1995 Mar;15(3):1389-97 PubMed

Sci Rep. 2017 Feb 20;7:41095 PubMed

Nat Struct Mol Biol. 2016 May;23 (5):426-33 PubMed

Cell Stem Cell. 2016 Aug 4;19(2):177-91 PubMed

Cell. 1993 Dec 31;75(7):1361-70 PubMed

J Biol Chem. 2016 Nov 25;291(48):24974-24985 PubMed

Neuron. 2017 May 17;94(4):713-730 PubMed

Cell Mol Life Sci. 2013 Jun;70(11):1875-95 PubMed

Cell Rep. 2017 Jun 20;19(12 ):2613-2626 PubMed

RNA. 2000 May;6(5):687-97 PubMed

Neuron. 2002 May 30;34(5):759-72 PubMed

J Clin Invest. 2012 Nov;122(11):4059-76 PubMed

J Neurosci. 2010 Sep 8;30(36):11917-25 PubMed

J Clin Neurosci. 2016 Oct;32:128-9 PubMed

Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11457-61 PubMed

RNA Biol. 2012 Aug;9(8):1054-65 PubMed

Genetica. 1999;106(1-2):37-47 PubMed

J Mol Biol. 2005 Aug 19;351(3):496-507 PubMed

Proc Natl Acad Sci U S A. 1962 Apr 15;48:613-6 PubMed

J Cell Sci. 2003 May 1;116(Pt 9):1805-18 PubMed

Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13532-6 PubMed

World J Biol Psychiatry. 2013 Dec;14(8):590-601 PubMed

Sci Rep. 2015 Oct 09;5:14941 PubMed

Curr Biol. 2012 Sep 11;22(17):R733-40 PubMed

Nat Rev Immunol. 2015 Jul;15(7):429-40 PubMed

Proc Natl Acad Sci U S A. 2013 Jan 15;110(3):1041-6 PubMed

J Biol Chem. 2003 Nov 14;278(46):45833-42 PubMed

Genome Res. 2009 Jun;19(6):978-86 PubMed

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace